2024

• Pan, Z., Alharthi, J., Bayoumi, A., George, J., Eslam, M. (2024). A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells. Frontiers in Bioscience - Landmark, 29(4), 148. [More Information]
• Zhang, H., Crespo, J., Grønbæk, H., Yang, W., Eslam, M., Wong, R., Machado, M., Yu, M., Ghanem, O., Okanoue, T., George, J., et al (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International. [More Information]
• Pan, Z., Bayoumi, A., Metwally, M., George, J., Eslam, M. (2024). Exportin 4 DNA promoter methylation in liver fibrosis. PloS One, 19(2024-05-05 00:00:00). [More Information]
• Abeysekera, K., Ginès, P., Thiele, M., Newsome, P., Guha, I., Eslam, M., Schattenberg, J., Alqahtani, S., Arrese, M., Berzigotti, A., et al (2024). Implementation of a liver health check in people with type 2 diabetes. The Lancet Gastroenterology & Hepatology, 9(1), 83-91. [More Information]
• Shiha, G., Waked, I., Eslam, M., Soliman, R., Hassan, A., Mousa, N., El-domiaty, N., Mikhail, N., Gameaa, R., Kobtan, A., et al (2024). Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR: Prospective study. Alimentary Pharmacology and Therapeutics. [More Information]
• Tu, T., Eslam, M., Berg, T., Chan, H., George, J., Douglas, M., Ajoyan, H., Nur Umami, R., Veeraraghavan, V., Boldbaatar, D., et al (2024). Inhibition of Cellular Factor TM6SF2 Suppresses Secretion Pathways of Hepatitis B, Hepatitis C, and Hepatitis D Viruses. The Journal of Infectious Diseases, 230(4), 970-981. [More Information]
• Pan, Z., Derbala, M., Al-Naamani, K., Ghazinian, H., Fan, J., Eslam, M. (2024). MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease. Annals of Hepatology, 29(5), 101512. [More Information]
• Pan, Z., Al-Busafi, S., Abdulla, M., Fouad, Y., Sebastiani, G., Eslam, M. (2024). MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatology International, 18(3), 964-972. [More Information]
• Pan, Z., Shiha, G., Esmat, G., Méndez-Sánchez, N., Eslam, M. (2024). MAFLD predicts cardiovascular disease risk better than MASLD. Liver International, 44(7), 1567-1574. [More Information]
• Eslam, M., George, J. (2024). MAFLD: from a disease framework to patient care. Hepatology International. [More Information]
• Pan, Z., Eslam, M. (2024). MERTK and Fibrosis: A New Target for Therapy. DNA and Cell Biology. [More Information]
• Choudhury, A., Singh, S., Desmukh, A., Sahoo, B., Eslam, M. (2024). Post-Liver Transplant Metabolic Syndrome. Journal of Clinical and Experimental Hepatology, 14(4), 101368. [More Information]
• Armandi, A., Ampuero, J., Pennisi, G., Aller, R., Tiniakos, D., Burt, A., David, E., Vecchio, F., Maggioni, M., Cabibi, D., Eslam, M., George, J., et al (2024). Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut, , 330815. [More Information]
• Tang, L., Jiang, P., Wang, C., Chen, Q., Byrne, C., Targher, G., Eslam, M., George, J., Wong, V., Zheng, M., et al (2024). Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International. [More Information]

2023

• Zhou, X., Targher, G., Byrne, C., Somers, V., Kim, S., Chahal, C., Wong, V., Cai, J., Shapiro, M., Eslam, M., et al (2023). An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatology International, 17(4), 773-791. [More Information]
• Fischer, J., Long, S., Koukoulioti, E., Müller, T., Fueloep, B., Heyne, R., Eslam, M., George, J., Finkelmeier, F., Waidmann, O., et al (2023). Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens, 12(1). [More Information]
• Ramírez-Mejía, M., Jiménez-Gutiérrez, C., Eslam, M., George, J., Méndez-Sánchez, N. (2023). Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification? Hepatology International. [More Information]
• Valenzuela-Vallejo, L., Papatheodoridis, G., Mingrone, G., George, J., Mantzoros, C., Chrysafi, P., Kouvari, M., Guatibonza-Garcia, V., Mylonakis, S., Katsarou, A., Eslam, M., et al (2023). Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study. Metabolism: Clinical and Experimental, 148, 155694. [More Information]
• Seto, W., Eslam, M. (2023). Comprehensive Guide to Hepatitis Advances. London: Elsevier. [More Information]
• Lu, H., George, J., Eslam, M., Villanueva, A., Bolondi, L., Reeves, H., McCain, M., Chambers, E., Ward, C., Sartika, D., et al (2023). Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. Liver Cancer, 12(1), 19-31. [More Information]
• Kouvari, M., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Polyzos, S., Deng, Y., Kokkorakis, M., Agraz, M., Mylonakis, S., Katsarou, A., Verrastro, O., Eslam, M., George, J., et al (2023). Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Metabolism: Clinical and Experimental, 147. [More Information]
• Alharthi, J., Pan, Z., Gloss, B., McLeod, D., Weltman, M., George, J., Eslam, M. (2023). Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism: Clinical and Experimental, 144. [More Information]
• Ramírez-Mejía, M., Qi, X., Abenavoli, L., Romero-Gomez, M., Eslam, M., Méndez-Sánchez, N. (2023). Metabolic dysfunction: The silenced connection with fatty liver disease. Annals of Hepatology, 28(6), 101138. [More Information]
• Pal, S., Castillo-Castañeda, S., Díaz-Orozco, L., Ramírez-Mejía, M., Dorantes-Heredia, R., Alonso-Morales, R., Eslam, M., Lammert, F., Méndez-Sánchez, N. (2023). Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study. Genes, 14(10). [More Information]
• Tang, L., Li, G., Eslam, M., Zhu, P., Chen, S., Leung, H., Huang, O., Wong, G., Zhou, Y., Karsdal, M., George, J., et al (2023). N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hepatology International, 17(1), 190-201. [More Information]
• Calzadilla-Bertot, L., Jeffrey, G., Wang, Z., Huang, Y., Garas, G., Wallace, M., De Boer, B., George, J., Eslam, M., Phu, A., et al (2023). Predicting liver-related events in NAFLD: A predictive model. Hepatology, 78(4), 1240-1251. [More Information]
• Fischer, J., van Bömmel, F., Koukoulioti, E., Müller, T., Heyne, R., Eslam, M., George, J., Finkelmeier, F., Waidmann, O., Berg, T. (2023). Sex-differences in the association of interleukin-10 and interleukin-12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatology Research, 53(12), 1156-1168. [More Information]
• Kouvari, M., Mylonakis, S., Katsarou, A., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Kokkorakis, M., Verrastro, O., Angelini, G., Markakis, G., Eslam, M., George, J., et al (2023). The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study. Diabetes Research and Clinical Practice, 203. [More Information]
• Canivet, C., Lange, N., Blanchet, O., Moal, V., Ibrahim Kamal Jouness, R., Roux, M., Chan, W., Sturm, N., Eslam, M., Bugianesi, E., George, J., et al (2023). Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients. Clinical Gastroenterology and Hepatology, 21(12), 3097-3106.e10. [More Information]

2022

• Alharthi, J., Bayoumi, A., Thabet, K., Pan, Z., Gloss, B., Latchoumanin, O., Lundberg, M., Twine, N., McLeod, D., Alenizi, S., Liddle, C., George, J., Eslam, M., et al (2022). A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nature Communications, 13(1). [More Information]
• Tang, L., Ma, H., Eslam, M., Wong, G., Zhu, P., Chen, S., Leeming, D., Karsdal, M., Li, G., Huang, O., George, J., et al (2022). Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism: Clinical and Experimental, 128, 154958. [More Information]
• Alharthi, J., Eslam, M. (2022). Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update. Journal of Clinical and Translational Hepatology, 10(1), 134-139. [More Information]
• Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F., Maggioni, M., Cabibi, D., Eslam, M., George, J., et al (2022). Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? Gut, 71(2), 382-390. [More Information]
• Jefferies, M., Rashid, H., Graham, R., Read, S., Banik, G., Lam, T., Njiomegnie, G., Eslam, M., Zhao, X., Ahmed, N., Douglas, M., George, J. (2022). COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines, 10(6). [More Information]
• Pal, S., Eslam, M., Mendez-Sanchez, N. (2022). Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones, 21(4), 573-589. [More Information]
• Willumsen, N., Jensen, C., Green, G., Nissen, N., Neely, J., Nelson, D., Pedersen, R., Frederiksen, P., Chen, I., Boisen, M., Eslam, M., George, J., et al (2022). Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. Cellular and Molecular Life Sciences, 79(4), 204. [More Information]
• Chan, K., Koh, T., Tang, A., Quek, J., Yong, J., Tay, P., Tan, D., Lim, W., Lin, S., Huang, D., Eslam, M., et al (2022). Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. Journal of Clinical Endocrinology and Metabolism, 107(9), 2691-2700. [More Information]
• Fukunaga, S., Nakano, D., Tsutsumi, T., Kawaguchi, T., Eslam, M., Yoshinaga, S., Abe, H., Nouno, R., Joh, S., Mitsuyama, K., George, J., et al (2022). Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatology Research, 52(8), 699-711. [More Information]
• Kawaguchi, T., Tsutsumi, T., Nakano, D., Eslam, M., George, J., Torimura, T. (2022). MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clinical and Molecular Hepatology, 28(2), 150-163. [More Information]
• Sarin, S., Eslam, M., Fan, J., Lin, H., George, J., Omata, M. (2022). MAFLD, patient-centred care, and APASL. Hepatology International, 16(5), 1032-1034. [More Information]
• Eslam, M., El-Serag, H., Francque, S., Sarin, S., Wei, L., Bugianesi, E., George, J. (2022). Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nature Reviews. Gastroenterology and Hepatology, 19(10), 638-651. [More Information]
• Alharthi, J., Gastaldelli, A., Cua, I., Ghazinian, H., Eslam, M. (2022). Metabolic dysfunction-associated fatty liver disease: A year in review. Current Opinion in Gastroenterology, 38(3), 251-260. [More Information]
• Shiha, G., Mikhail, N., Soliman, R., Hassan, A., Eslam, M. (2022). Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study. Hepatology International, 16(1), 159-170. [More Information]
• Attia, D., Abdel Alem, S., El-Akel, W., Abdel-Razek, W., Eslam, M., Fouad, Y., Waked, I. (2022). Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection—a population-based study. Alimentary Pharmacology and Therapeutics, 56(11-12), 1581-1590. [More Information]
• Al-Omary, A., Blyth, K., Weltman, M., George, J., Eslam, M. (2022). The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. Journal of Digestive Diseases, 23(1), 33-43. [More Information]
• Metwally, M., Berg, T., Tsochatzis, E., Eslam, M. (2022). Translation Reprogramming as a Novel Therapeutic Target in MAFLD. Advanced Biology, 6(5). [More Information]

2021

• Eslam, M., Wong, G., Hashem, A., Chan, H., Nielsen, M., Leeming, D., Chan, A., Chen, Y., Duffin, K., Karsdal, M., George, J., et al (2021). A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. American Journal of Gastroenterology, 116(5), 984-993. [More Information]
• Calzadilla-Bertot, L., Vilar-Gomez, E., Wong, V., Romero-Gomez, M., Aller-de la Fuente, R., Wong, G., Castellanos, M., Eslam, M., Desai, A., Jeffrey, G., George, J., et al (2021). ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology, 73(6), 2238-2250. [More Information]
• Zhou, G., Bae, D., Nguyen, R., Huo, X., Han, S., Zhang, Z., Hebbard, L., Duan, W., Eslam, M., Liddle, C., Qiao, L., George, J., et al (2021). An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. Cancer Letters, 501, 124-132. [More Information]
• Pan, Z., Fan, J., Eslam, M. (2021). An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Current Opinion in Pharmacology, 60, 170-176. [More Information]
• Liu, W., Eslam, M., Zheng, K., Ma, H., Rios, R., Lv, M., Li, G., Tang, L., Zhu, P., Wang, X., George, J., et al (2021). Associations of hydroxysteroid 17-beta dehydrogenase 13 variants with liver histology in chinese patients with metabolic-associated fatty liver disease. Journal of Clinical and Translational Hepatology, 9(2), 194-202. [More Information]
• Metwally, M., Bayoumi, A., Khan, A., Adams, L., Aller, R., García-Monzón, C., Arias-Loste, M., Bugianesi, E., Miele, L., Anna, A., Latchoumanin, O., Han, S., Alenizi, S., El Sharkawy, R., Elattar, A., Liddle, C., George, J., Eslam, M., et al (2021). Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 70, 103521. [More Information]
• Eslam, M., Alkhouri, N., Vajro, P., Baumann, U., Weiss, R., Socha, P., Marcus, C., Lee, W., Kelly, D., Porta, G., Baur, L., George, J., et al (2021). Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. The Lancet Gastroenterology & Hepatology, 6(10), 864-873. [More Information]
• Shiha, G., Soliman, R., Mikhail, N., Hassan, A., Eslam, M. (2021). Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score. Liver International, 41(11), 2768-2776. [More Information]
• Kuscuoglu, D., Bewersdorf, L., Wenzel, K., Gross, A., Kobazi Ensari, G., Luo, Y., Kilic, K., Hittatiya, K., Golob-Schwarzl, N., Leube, R., George, J., Metwally, M., Eslam, M., et al (2021). Dual proteotoxic stress accelerates liver injury via activation of p62-Nrf2. Journal of Pathology, 254(1), 80-91. [More Information]
• Mendez-Sanchez, N., Córdova-Gallardo, J., Barranco-Fragoso, B., Eslam, M. (2021). Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis. Frontiers in Immunology, 12, 641240. [More Information]
• Eslam, M., Ahmed, A., Després, J., Jha, V., Halford, J., Wei Chieh, J., Harris, D., Nangaku, M., Colagiuri, S., Targher, G., George, J., et al (2021). Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. The Lancet Gastroenterology & Hepatology, 6(9), 743-753. [More Information]
• Tsutsumi, T., Eslam, M., Kawaguchi, T., Yamamura, S., Kawaguchi, A., Nakano, D., Koseki, M., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., et al (2021). MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatology Research, 51(11), 1115-1128. [More Information]
• Eslam, M., George, J. (2021). MAFLD: A game changer redefining fatty liver disease for adults and children. Journal of Hepatology, 74(4), 992-994. [More Information]
• Eslam, M., George, J. (2021). MAFLD: A holistic view to redefining fatty liver disease. Journal of Hepatology, 74(4), 983-985. [More Information]
• Eslam, M., George, J. (2021). MAFLD: Now is the time to capitalize on the momentum. Journal of Hepatology, 74(5), 1262-1263. [More Information]
• Booth, D., Ahlenstiel, G., George, J., O'Connor, K., Eslam, M. (2021). A method to predict rate of fibrosis in liver diseases. Patent No. 10,939,868.
• Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L., Aller, R., Khan, A., García-Monzón, C., Arias-Loste, M., Miele, L., Latchoumanin, O., Alenizi, S., Metwally, M., Qiao, L., Liddle, C., George, J., Eslam, M., et al (2021). Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Advanced Science, 8(11), 2004168. [More Information]
• Fukunaga, S., Nakano, D., Kawaguchi, T., Eslam, M., Ouchi, A., Nagata, T., Kuroki, H., Kawata, H., Abe, H., Nouno, R., George, J., et al (2021). Non-obese mafld is associated with colorectal adenoma in health check examinees: A multicenter retrospective study. International Journal of Molecular Sciences, 22(11), 5462. [More Information]
• Grimaudo, S., Dongiovanni, P., Pihlajamäki, J., Eslam, M., Yki-Järvinen, H., Pipitone, R., Baselli, G., Cammà, C., Di Marco, V., Enea, M., George, J., et al (2021). NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 41(11), 2712-2719. [More Information]
• Shiha, G., Korenjak, M., Eskridge, W., Casanovas, T., Velez-Moller, P., Högström, S., Richardson, B., Munoz, C., Sigurðardóttir, S., Coulibaly, A., Eslam, M., et al (2021). Redefining fatty liver disease: an international patient perspective. The Lancet Gastroenterology & Hepatology, 6(1), 73-79. [More Information]
• Shiha, G., Soliman, R., Mikhail, N., Eslam, M. (2021). Reply to: Suboptimal accuracy of GES score to stratify post SVR HCC risk in a single-centre cohort of European cirrhotics. Liver International, 41(5), 1155-1156. [More Information]
• Alam, S., Eslam, M., SKM Hasan, N., Anam, K., Chowdhury, M., Khan, M., Hasan, M., Mohamed, R. (2021). Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta-analysis. JGH Open, 5(11), 1236-1249. [More Information]
• Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V., Castellanos, M., Aller-de la Fuente, R., Eslam, M., Wong, G., George, J., Romero-Gomez, M., Adams, L. (2021). Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis. Clinical Gastroenterology and Hepatology, 19(1), 136-145.e6. [More Information]
• Eslam, M., Ratziu, V., George, J. (2021). Yet more evidence that MAFLD is more than a name change. Journal of Hepatology, 74(4), 977-979. [More Information]

2020

• Eslam, M., Newsome, P., Sarin, S., Anstee, Q., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J., Schattenberg, J., George, J., et al (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 73(1), 202-209. [More Information]
• Jensen, C., Nielsen, S., Eslam, M., Genovese, F., Nielsen, M., Vongsuvanh, R., Uchila, R., van der Poorten, D., George, J., Karsdal, M., et al (2020). Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. Journal of Hepatocellular Carcinoma, 7, 301-313. [More Information]
• Targher, G., Mantovani, A., Byrne, C., Wang, X., Yan, H., Sun, Q., Pan, K., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes and Metabolism, 46(6), 505-507. [More Information]
• Zheng, K., Fan, J., Shi, J., Wong, V., Eslam, M., George, J., Zheng, M. (2020). From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chinese Medical Journal, 133(19), 2271-2273. [More Information]
• Eslam, M., George, J. (2020). Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nature Reviews. Gastroenterology and Hepatology, 17(1), 40-52. [More Information]
• Bayoumi, A., Jalil, I., Metwally, M., Adams, L., Aller, R., García-Monzón, C., Arias-Loste, M., Miele, L., Petta, S., Craxì, A., Qiao, L., Liddle, C., George, J., Eslam, M., et al (2020). Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PloS One, 15, e0243590. [More Information]
• Shiha, G., Waked, I., Soliman, R., Elbasiony, M., Gomaa, A., Mikhail, N., Eslam, M. (2020). GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals. Liver International, 40(11), 2828-2833. [More Information]
• Chen, F., Esmaili, S., Rogers, G., Bugianesi, E., Petta, S., Marchesini, G., Bayoumi, A., Metwally, M., Azardaryany, M., Coulter, S., Liddle, C., George, J., Eslam, M., et al (2020). Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology, 71(4), 1213-1227. [More Information]
• Sarin, S., Kumar, M., Eslam, M., George, J., Al Mahtab, M., Akbar, S., Jia, J., Tian, Q., Aggarwal, R., Muljono, D., et al (2020). Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology, 5(2), 167-228. [More Information]
• Schneider, C., Hamesch, K., Gross, A., Mandorfer, M., Moeller, L., Pereira, V., Pons, M., Kuca, P., Reichert, M., Benini, F., Eslam, M., George, J., et al (2020). Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. Gastroenterology, 159(2), 534-5.48. [More Information]
• Alharthi, J., Latchoumanin, O., George, J., Eslam, M. (2020). Macrophages in metabolic associated fatty liver disease. World Journal of Gastroenterology, 26(16), 1861-1878. [More Information]
• Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., Torimura, T. (2020). MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver International, 40(12), 3018-3030. [More Information]
• Eslam, M., Sanyal, A., George, J. (2020). MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158(7), 1999-2014. [More Information]
• Eslam, M., Chen, F., George, J. (2020). NAFLD in Lean Asians. Clinical Liver Disease, 16(6), 240-243. [More Information]
• Eslam, M., Fan, J., Mendez-Sanchez, N. (2020). Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. The Lancet Gastroenterology & Hepatology, 5(8), 713-715. [More Information]
• Targher, G., Mantovani, A., Wang, X., Yan, H., Sun, Q., Pan, K., Byrne, C., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes and Metabolism, 46(4), 335-337. [More Information]
• Eslam, M., George, J. (2020). Reply to: Correspondence on “A new definition for metabolic associated fatty liver disease: an international expert consensus statement”: MAFLD: Moving from a concept to practice. Journal of Hepatology, 73(5), 1268-1269. [More Information]
• Eslam, M., George, J. (2020). Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”: Bringing evidence to the NAFLD-MAFLD debate. Journal of Hepatology, 73(6), 1575. [More Information]
• Targher, G., Mantovani, A., Byrne, C., Wang, X., Yan, H., Sun, Q., Pan, K., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut, 69(8), 1545-1547. [More Information]
• Eslam, M., Sarin, S., Wong, V., Fan, J., Kawaguchi, T., Ahn, S., Zheng, M., Shiha, G., Yilmaz, Y., Gani, R., George, J., et al (2020). The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 14(6), 889-919. [More Information]
• Bayoumi, A., Gronbaek, H., George, J., Eslam, M. (2020). The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends in Genetics, 36(6), 429-441. [More Information]
• Méndez-Sánchez, N., Valencia-Rodríguez, A., Qi, X., Yoshida, E., Romero-Gomez, M., George, J., Eslam, M., Abenavoli, L., Xie, W., Teschke, R., et al (2020). What has the COVID-19 pandemic taught us so far? Addressing the problem from a hepatologist’s perspective. Journal of Clinical and Translational Hepatology, 8(2), 24. [More Information]
• Zheng, K., Eslam, M., George, J., Zheng, M. (2020). When a new definition overhauls perceptions of MAFLD related cirrhosis care. Hepatobiliary Surgery and Nutrition, 9(6), 801-804. [More Information]

2019

• Metwally, M., Bayoumi, A., Romero-Gomez, M., Thabet, K., John, M., Adams, L., Huo, X., Aller, R., Garcia-Monzon, C., Arias-Loste, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3 ' UTR. Journal of Hepatology, 70(3), 494-500. [More Information]
• El Sharkawy, R., Bayoumi, A., Metwally, M., Mangia, A., Berg, T., Romero-Gomez, M., Abate, M., Irving, W., Sheridan, D., Dore, G., Latchoumanin, O., Thabet, K., Najim, M., Douglas, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports, 9(1), 1-10. [More Information]
• Daniels, S., Leeming, D., Eslam, M., Hashem, A., Nielsen, M., Krag, A., Karsdal, M., Grove, J., Neil Guha, I., Kawaguchi, T., George, J., et al (2019). ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology, 69(3), 1075-1086. [More Information]
• Eslam, M., George, J. (2019). Genetic Insights for Drug Development in NAFLD. Trends In Pharmacological Sciences, 40(7), 506-516. [More Information]
• Metwally, M., Thabet, K., Bayoumi, A., Nikpour, M., Stevens, W., Sahhar, J., Zochling, J., Roddy, J., Tymms, K., Strickland, G., Liddle, C., Manolios, N., George, J., Eslam, M., et al (2019). IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports, 9(1), 1-5. [More Information]
• Eslam, M., Ahlenstiel, G., George, J. (2019). Interferon Lambda and Liver Fibrosis. Journal of Interferon and Cytokine Research, 39(10), 627-635. [More Information]
• Wijaya, R., Read, S., Schibeci, S., Eslam, M., Azardaryany, M., El-Khobar, K., van der Poorten, D., Lin, R., Yuen, L., Lam, V., George, J., Douglas, M., Ahlenstiel, G. (2019). KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. Journal of Hepatology, 71(2), 252-264. [More Information]
• Scott, C., Stokes, R., Cha, K., Clouston, A., Eslam, M., Metwally, M., Swarbrick, M., George, J., Gunton, J. (2019). Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. PloS One, 14(12), 1-20. [More Information]
• Eslam, M., George, J. (2019). Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease. Hepatology International, 13(6), 662-664. [More Information]
• Wong, M., Huang, J., George, J., Huang, J., Leung, C., Eslam, M., Chan, H., Ng, S. (2019). The changing epidemiology of liver diseases in the Asia-Pacific region. Nature Reviews. Gastroenterology and Hepatology, 16(1), 57-73. [More Information]
• Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K., George, J., Eslam, M., Gronbaek, H., Hartmann, R. (2019). The role of IFN in the development of NAFLD and NASH. Cytokine, 124, 1-6. [More Information]
• Eslam, M., Sanyal, A., George, J. (2019). Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology, 157(3), 590-593. [More Information]

2018

• El Sharkawy, R., George, J., Eslam, M. (2018). Editorial: STAT-4 polymorphism - a tool to personalise clinical practice in chronic HBV infection Authors' reply. Alimentary Pharmacology and Therapeutics, 48(7), 769-770. [More Information]
• Eslam, M., George, J. (2018). Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. Alimentary Pharmacology and Therapeutics, 47(7), 1038-1039. [More Information]
• Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V., Castellanos, M., de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quinones Sanz, M., Conde-Martin, A., George, J., et al (2018). Fibrosis Severity as a Determinant of Cause-specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease. Gastroenterology, 155(2), 443-457.e17. [More Information]
• Eslam, M., Valenti, L., Romeo, S. (2018). Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology, 68(2), 268-279. [More Information]
• Younossi, Z., Anstee, Q., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews. Gastroenterology and Hepatology, 15(1), 11-20. [More Information]

2017

• Baatarkhuu, O., Lee, H., George, J., Munkh-Orshikh, D., Enkhtuvshin, B., Ariunaa, S., Eslam, M., Ahn, S., Han, K., Kim, D. (2017). Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. Clinical and Molecular Hepatology, 23(2), 147-153. [More Information]
• Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature Genetics, 49(5), 795-800. [More Information]
• Petta, S., Eslam, M., Valenti, L., Bugianesi, E., Barbara, M., Camma, C., Porzio, M., Rosso, C., Fargion, S., George, J., et al (2017). Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver International, 37(9), 1389-1396. [More Information]
• Thabet, K., Chan, H., Petta, S., Mangia, A., Berg, T., Boonstra, A., Brouwer, W., Abate, M., Wong, V., Nazmy, M., Liddle, C., George, J., Eslam, M., et al (2017). The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology, 65(6), 1840-1850. [More Information]
• John, M., Metwally, M., Mangia, A., Romero-Gomez, M., Berg, T., Sheridan, D., George, J., Eslam, M. (2017). TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. Gastroenterology, 153(5), 1448-1449. [More Information]

2016

• Eslam, M., Mangia, A., Berg, T., Chan, H., Irving, W., Dore, G., Abate, M., Bugianesi, E., Adams, L., Najim, M., Weltman, M., Rahme, A., Booth, D., Liddle, C., Douglas, M., van der Poorten, D., George, J., White, R., Leung, R., et al (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 64(1), 34-46. [More Information]
• Eslam, M., Hashem, A., Romero-Gomez, M., Berg, T., Dore, G., Mangia, A., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Kelaeng, K., Ahlenstiel, G., Liddle, C., Douglas, M., Booth, D., George, J., et al (2016). FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 64(2), 390-398. [More Information]
• Eslam, M., George, J. (2016). Genetic and epigenetic mechanisms of NASH. Hepatology International, 10(3), 394-406. [More Information]
• O'Connor, K., Read, S., Wang, X., Schibeci, S., Eslam, M., Ong, A., Weltman, M., Douglas, M., Mazzola, A., Craxi, A., Stewart, G., Liddle, C., George, J., Ahlenstiel, G., Booth, D., et al (2016). IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity, 17(6), 328-334. [More Information]
• Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W., Berg, T., Dore, G., Gronbaek, H., Sheridan, D., Weltman, M., White, R., Douglas, M., Liddle, C., van der Poorten, D., George, J., Eslam, M., et al (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7, 1-8. [More Information]
• Asimakopoulos, A., Mangia, A., Dore, G., Lloyd, A., George, J., Eslam, M. (2016). Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans. Hepatology, 64(6), 2264-2265. [More Information]
• Eslam, M., George, J. (2016). Targeting IFN-lambda: Therapeutic Implications. Expert Opinion on Therapeutic Targets, 20(12), 1425-1432. [More Information]
• Kazankov, K., Barrera Martinez, F., Moller, H., Rosso, C., Bugianesi, E., David, E., Jouness, R., Esmaili, S., Eslam, M., McLeod, D., George, J., et al (2016). The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver International, 36(10), 1549-1557. [More Information]

2015

• Eslam, M., George, J. (2015). Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution. Seminars in Liver Disease, 35(4), 402-420. [More Information]
• Eslam, M., Hashem, A., Leung, R., Romero-Gomez, M., Berg, T., Dore, G., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Douglas, M., Liddle, C., Booth, D., George, J., Ahlenstiel, G., et al (2015). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 6, 1-10. [More Information]
• Eslam, M., George, J. (2015). Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? Hepatology International, 9(1), 5-8. [More Information]
• Petta, S., Vanni, E., Bugianesi, E., Rosso, C., Cabibi, D., Camma, C., Di Marco, F., Eslam, M., Grimaudo, S., Macaluso, F., McLeod, D., George, J., et al (2015). PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Alimentary Pharmacology and Therapeutics, 41(10), 939-948. [More Information]

2014

• Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]

2013

• Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 19(41), 7055-7061. [More Information]